Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TT26PHO)

• DTT Name: Mineralocorticoid receptor (MR) DTT Info
• Gene Name: NR3C2

Molecule-Related Drug & Molecule List

8 Approved Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Aldosterone	DM9S2JW	Hypertension	BA00-BA04	Approved	[1]
Desoxycorticosterone Acetate	DMS0AFE	Discovery agent	N.A.	Approved	[2]
Desoxycorticosterone Pivalate	DMSA4B3	Addison disease	5A74.0	Approved	[3]
Drospirenone	DM1A9W3	Acne vulgaris	ED80	Approved	[4]
Eplerenone	DMF0NQR	Heart failure	BD10-BD13	Approved	[2]
Finerenone	DMM4FJ3	Chronic kidney disease	GB61	Approved	[5]
Fludrocortisone	DMUDIR8	Addison disease	5A74.0	Approved	[6]
Spironolactone	DM2AQ5N	Chronic heart failure	BD1Z	Approved	[2]

9 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
AZD9977	DM3LFDH	Heart failure	BD10-BD13	Phase 2	[7]
BR-4628	DMNFKVW	Heart failure	BD10-BD13	Phase 2	[8]
LY-2623091	DMFGNB4	Chronic kidney disease	GB61	Phase 2	[9]
MT-3995	DMXSZA4	Diabetic nephropathy	GB61.Z	Phase 2	[9]
Nerenone	DMBJ3GL	Diabetic nephropathy	GB61.Z	Phase 2	[8]
ZK-91587	DMJ94L0	Cardiovascular disease	BA00-BE2Z	Phase 2	[10]
KBP-5074	DMI9FXE	Hypertension	BA00-BA04	Phase 1/2	[11]
XL550	DMY93SW	Type-2 diabetes	5A11	Phase 1	[12]
SP 20202	DMOVGXM	Diabetic nephropathy	GB61.Z	Clinical trial	[13]

6 Patented Agent(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PMID27551786-Compound-106	DM5OQBR	N. A.	N. A.	Patented	[14]
PMID27551786-Compound-138	DM4IZUH	N. A.	N. A.	Patented	[14]
PMID27551786-Compound-I	DMA7H63	N. A.	N. A.	Patented	[14]
PMID27551786-Compound-II	DMJADXV	N. A.	N. A.	Patented	[14]
PMID27551786-Compound-III	DMBQ981	N. A.	N. A.	Patented	[14]
PMID27551786-Compound-IV	DM7IB8L	N. A.	N. A.	Patented	[14]

1 Discontinued Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PF-03882845	DMOS9NZ	Diabetic nephropathy	GB61.Z	Terminated	[15]

10 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
(11-BETA)-11,21-DIHYDROXY-PREGN-4-ENE-3,20-DIONE	DMTPQ84	Discovery agent	N.A.	Investigative	[16]
AL-43	DMLEDHR	Discovery agent	N.A.	Investigative	[17]
B-Octylglucoside	DMMO75G	Discovery agent	N.A.	Investigative	[18]
CB-1922	DMSFXZU	Human immunodeficiency virus infection	1C62	Investigative	[8]
deoxycorticosterone	DMW6YLS	Discovery agent	N.A.	Investigative	[19]
Epierenone	DMVZW92	Discovery agent	N.A.	Investigative	[20]
LG-120838	DMG1UOR	Discovery agent	N.A.	Investigative	[21]
LGD-5552	DM67KWM	Discovery agent	N.A.	Investigative	[22]
RU28318	DMN049T	Discovery agent	N.A.	Investigative	[8]
WAY-255348	DMSLNWA	Solid tumour/cancer	2A00-2F9Z	Investigative	[23]

References

• [1] Stimulation of testosterone production in rat Leydig cells by aldosterone is mineralocorticoid receptor mediated. Mol Cell Endocrinol. 2005 Nov 24;243(1-2):35-42.
• [2] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [3] Characterization of rat brain aldosterone receptors reveals high affinity for corticosterone. Endocrinology. 1983 Dec;113(6):2043-51.
• [4] Biochemical mechanisms of New Molecular Entities (NMEs) approved by United States FDA during 2001-2004: mechanisms leading to optimal efficacy and ... Curr Top Med Chem. 2006;6(5):461-78.
• [5] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [6] Mineralocorticoid receptor-mediated inhibition of the hypothalamic-pituitary-adrenal axis in aged humans. J Gerontol A Biol Sci Med Sci. 2003 Oct;58(10):B900-5.
• [7] The selective mineralocorticoid receptor modulator AZD9977 reveals differences in mineralocorticoid effects of aldosterone and fludrocortisone. J Renin Angiotensin Aldosterone Syst. 2019 Jan-Mar;20(1):1470320319827449.
• [8] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 626).
• [9] Nonsteroidal antagonists of the mineralocorticoid receptor. Curr Opin Nephrol Hypertens. 2015 Sep;24(5):417-24.
• [10] ZK91587: a novel synthetic antimineralocorticoid displays high affinity for corticosterone (type I) receptors in the rat hippocampus. Life Sci. 1988;43(19):1537-43.
• [11] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [12] Clinical pipeline report, company report or official report of Exelixis (2011).
• [13] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2023. Adis Insight
• [14] Mineralocorticoid receptor antagonists: a patent evaluation of US20150284376A1.Expert Opin Ther Pat. 2016 Sep 14:1-4.
• [15] Discovery of (3S,3aR)-2-(3-chloro-4-cyanophenyl)-3-cyclopentyl-3,3a,4,5-tetrahydro-2H-benzo[g] indazole-7-carboxylic acid (PF-3882845), an orally efficacious mineralocorticoid receptor (MR) antagonist for hypertension and nephropathy.J Med Chem.2010 Aug 26;53(16):5979-6002.
• [16] The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
• [17] Nonsteroidal selective glucocorticoid modulators: the effect of C-10 substitution on receptor selectivity and functional potency of 5-allyl-2,5-dih... J Med Chem. 2003 Mar 13;46(6):1016-30.
• [18] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [19] Pharmacological and functional characterization of human mineralocorticoid and glucocorticoid receptor ligands. Eur J Pharmacol. 1993 Oct 15;247(2):145-54.
• [20] (S)-N-{3-[1-cyclopropyl-1-(2,4-difluoro-phenyl)-ethyl]-1H-indol-7-yl}-methanesulfonamide: a potent, nonsteroidal, functional antagonist of the mine... J Med Chem. 2007 Dec 27;50(26):6443-5.
• [21] 5-Benzylidene 1,2-dihydrochromeno[3,4-f]quinolines, a novel class of nonsteroidal human progesterone receptor agonists. J Med Chem. 1998 Oct 22;41(22):4354-9.
• [22] Antiinflammatory glucocorticoid receptor ligand with reduced side effects exhibits an altered protein-protein interaction profile. Proc Natl Acad Sci U S A. 2007 Dec 4;104(49):19244-9.
• [23] Design, synthesis, and SAR of new pyrrole-oxindole progesterone receptor modulators leading to 5-(7-fluoro-3,3-dimethyl-2-oxo-2,3-dihydro-1H-indol-... J Med Chem. 2008 Mar 27;51(6):1861-73.